Advertisement

Topics

GSK wins $235 million from Teva in Coreg patent trial

19:49 EDT 21 Jun 2017 | Reuters

(Reuters) - A U.S. jury has ordered Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc more than $235 million for infringing a patent covering its blood pressure drug Coreg, court documents showed.

Original Article: GSK wins $235 million from Teva in Coreg patent trial

NEXT ARTICLE

More From BioPortfolio on "GSK wins $235 million from Teva in Coreg patent trial"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

GlaxoSmithKline
GlaxoSmithKline is the third largest pharmaceutical company in the world, based on annual sales, which reached $37,134m in 2009. Spread over 100 countries, GSK employs 96,500 people, 13,000 of which are dedicated to research and development of the the ...